mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue

Anticancer Research

Volumn 23, Issue 3 B, 2003, Pages 2617-2624

  Lichtinghagen, Ralf ^a   Musholt, Petra B ^a   Stephan, Carsten ^b   Lein, Michael ^b   Kristiansen, Glen ^b   Hauptmann, Steffen ^b   Rudolph, Birgit ^b   Schnorr, Dietmar ^b   Loening, Stefan A ^b   Jung, Klaus ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Matrix metalloproteinases; MRNA expression; Prostate carcinoma; Real time quantitative PCR; Tissue inhibitors of matrix metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; AGED; GENE EXPRESSION PROFILING; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0041805562     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Woessner JF: The family of matrix metalloproteinases. Ann N Y Acad Sci 732: 11-21, 1994.
2. Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51 (Suppl): 5054S-5059S, 1991.
3. Curran S and Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36: 1621-1630, 2000.
4. De Clerck YA, Shimada H, Taylor SM and Langley KE: Matrix metalloproteinases and their inhibitors in tumor progression. Ann N Y Acad Sci 732: 222-232, 1994.
5. Wilson MJ: Proteases in prostate development, function, and pathology. Microsc Res Techniq 30: 305-318, 1995.
6. Wilson MJ, Kapoor S, Vogel MM and Sinha AA: Characterization of gelatin-degrading metalloproteinase activities of the Dunning rat prostate tumor grown in nude mice. Prostate 19: 237-250, 1991.
7. Powell WC, Knox JD, Navre M, Grogan TM, Kittelson J, Nagle RB and Bowden GT: Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53: 417-422, 1993.
8. Stearns ME, Fudge K, Garcia F and Wang M: IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metastasis 17: 62-74; 1997.
9. Huang CC, Wu CH and Abramson M: Collagenase activity in cultures of rat prostate carcinoma. Biochim Biophys Acta 570: 149-156, 1979.
10. Stearns ME and Wang M: Regulation of kinesin expression and type IV collagenase secretion in invasive human prostate PC-3 tumor sublines. Cancer Res 51: 5866-5875, 1991.
11. Stearns M, Wang M and Stearns ME: Cytokine (IL-10, IL-6) induction of tissue inhibitor of metalloproteinase 1 in primary human prostate tumor cell lines. Oncol Res 7: 173-181, 1995.
12. Wang M, Fudge K, Rhim JS and Stearns ME: Cytokine regulation of the matrix metalloproteinases and their inhibitors in human papillomavirus-18 transformed human prostatic tumor cell lines. Oncol Res 8: 303-315, 1996.
13. Lokeshwar BL, Selzer MG, Block NL and Gunja-Smith Z: Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 53: 4493-4498, 1993.
14. Festuccia C, Bologna M, Vicentini C, Tacconelli A, Miano R, Violini S and Mackay AR: Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int J Cancer 69: 386-393, 1996.
15. Festuccia C, Angelucci A, Gravina GL, Villanova I, Teti A, Abini A and Bologna M: Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer 85: 407-415, 2000.
16. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, Anderson JB, Williams JL and Rees RC: Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Brit J Cancer 69: 177-182, 1994.
17. Stearns M and Stearns ME: Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 8: 69-75, 1996.
18. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M and Stearns ME: In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 15: 246-258, 1997.
19. Sobin LH and Wittekind C: TNM Classification of Malignant Tumours. New York, Wiley-Liss, 1997, 171-173.
20. Meyer A, Jung K, Lein M, Schnorr D and Loening SA: Factors influencing the ratio of free to total prostate specific antigen in serum. Int J Cancer 74; 630-636, 1997.
21. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM and Isaacs WB: Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61: 4683-4688, 2001.
22. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klaren R, Grone EF, Wiesel M, Gudemann C, Kuster J, Schott W, Staehler G, Kretzler M, Hollstein M and Grone HJ: Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 160: 2169-2180, 2002.
23. Lichtinghagen R, Huegel O, Seifert T, Haberkorn CI, Michels D, Flemming P, Bahr M and Boeker KH: Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 46: 183-192, 2000.
24. Lichtinghagen R and Glaubitz R: A competitive polymerase chain reaction assay for reliable identification of Bordetella pertussis in nasopharyngeal swabs. Eur J Clin Chem Clin Biochem 33: 87-93, 1995.
25. Lichtinghagen R, Helmbrecht T, Arndt B, and Boker KH: Expression pattern of matrix metalloproteinases in human liver. Eur J Clin Chem Clin Biochem 33: 65-71, 1995.
26. Still K, Robson CN, Autzen P, Robinson MC and Hamdy FC: Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 42: 18-25, 2000.
27. Sternlicht MD and Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516, 2001.
28. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
29. Varani J, Hattori Y, Dame MK, Schmidt T, Murphy HS, Johnson KJ and Wojno KJ: Matrix metalloproteinases (MMPs) in fresh human prostate tumour tissue and organ-cultured prostate tissue: levels of collagenolytic and gelatinolytic MMPs are low, variable and different in fresh tissue versus organ-cultured tissue. Br J Cancer 84: 1076-1083, 2001.
30. Hashimoto K, Kihira Y, Matuo Y and Usui T: Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 160: 1872-1876, 1998.
31. Knox JD, Wolf C, McDaniel K, Clark V, Loriot M, Bowden GT and Nagle RB: Matrilysin expression in human prostate carcinoma. Mol Carcinog 15: 57-63, 1996.
32. Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, Sakr W, Grignon DJ and Cher ML: Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 5: 4105-4110, 1999.
33. Jung K, Krell H-W, Ortel B, Hasan T, Römer A, Schnorr D, Loening SA and Lein M: Blood matrix metalloproteinase 9 as biomarker of the prostate cancer progression in Dunning (Copenhagen) rats. Prostate in press: 2002.
34. Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25: 169-193, 2000.
35. Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R and Zhang Z: Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 166: 2171-2177, 2001.
36. Jung K, Lein M, Ulbrich N, Rudolph B, Henke W, Schnorr D, and Loening SA: Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspects. Prostate 34: 130-136, 1998.
37. Lein M, Jung K, Ortel B, Stephan C, Rothaug W, Johannsen M, Deger S, Schnorr D, Loening S and Krell H-W: The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 21: 2089-2096, 2002.